SCHEMBL6793165

SCHEMBL6793165

CCCc1ccc(S(C)(=O)=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.67
PTGS2 P35354 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
FFAR4 Q5NUL3 1/20 0.50
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ENPP2 Q13822 1/20 0.48
KCNJ1 P48048 1/20 0.46
KCNH2 Q12809 1/20 0.46
CNR2 P34972 1/20 0.46
THRB P10828 1/20 0.46
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.45
PSMB5 P28074 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216900 0.87 CA2 (0.69) CA2SMN1; SMN2FFAR4ALDH1A1LMNA
SCHEMBL14018319 0.85 CA2 (0.70) CA2PTGS2SMN1; SMN2MEN1ALDH1A1
SCHEMBL31681202 0.84 ATM (0.63) CA2FFAR4MEN1ALDH1A1LMNA
SCHEMBL11889489 0.84 CA2 (0.69) CA2SMN1; SMN2FFAR4MEN1ALDH1A1
SCHEMBL12204115 0.84 CA2 (0.68) CA2PTGS2SMN1; SMN2MEN1ALDH1A1
SCHEMBL22792207 0.84 CA2 (0.68) CA2PTGS2SMN1; SMN2MEN1ALDH1A1
SCHEMBL20883032 0.84 CA2 (0.68) CA2PTGS2SMN1; SMN2MEN1ALDH1A1
SCHEMBL12040857 0.84 CA2 (0.68) CA2PTGS2SMN1; SMN2MEN1ALDH1A1
SCHEMBL10182183 0.82 CA2 (0.67) CA2SMN1; SMN2FFAR4MEN1ALDH1A1
SCHEMBL330903 0.82 CA2 (0.67) CA2SMN1; SMN2FFAR4MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3324977-B1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-07-13 EP disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed
US-20220155688-A1 ALKALINE DEVELOPER SOLUABLE SILICON-CONTAINING RESIST UNDERLAYER FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2022-05-19 US disclosed
US-20200207809-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2020-07-02 US disclosed
CN-107848947-A Fluorochemical, living polymerization initiator, fluoropolymer, the manufacture method of fluoropolymer and anti-corrosion agent composition DIC株式会社 2018-03-27 CN disclosed
US-20180066007-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2018-03-08 US disclosed
US-20180066007-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2018-03-08 US disclosed
US-RE46630-E1 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) 2017-12-12 US disclosed
US-20170334823-A1 METHODS FOR PRODUCING FUELS, GASOLINE ADDITIVES, AND LUBRICANTS USING AMINE CATALYSTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-23 US disclosed
US-20170327448-A1 METHODS FOR PRODUCING FUELS, GASOLINE ADDITIVES, AND LUBRICANTS USING AMINE CATALYSTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-16 US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 US disclosed
US-20080027060-A1 DIPEPTIDE NITRILES ALTMANN EVA 2008-01-31 US disclosed
US-20080027060-A1 DIPEPTIDE NITRILES ALTMANN EVA 2008-01-31 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
EP-1820503-A2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them Pfizer Italia S.r.l. (IT) 2007-08-22 EP disclosed
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use IPSEN PHARMA S.A.S. (FR) 2007-02-22 US disclosed
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-08 US disclosed
WO-2004056823-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-08 WO disclosed
WO-2004024728-A2 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE SPHK1, SPHK2, S1PR2 CA2 2362/4885PTGS2 638/4885SMN1; SMN2 2253/4885
US-20200207809-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, CTRL, ENPEP CA2 2595/4885PTGS2 485/4885SMN1; SMN2 2362/4885
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CA2 4226/4885PTGS2 3441/4885SMN1; SMN2 4057/4885
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SSTR2, SSTR5, SSTR3 CA2 771/4885PTGS2 1185/4885SMN1; SMN2 1973/4885
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same VIP, PROKR1, PGC CA2 3768/4885PTGS2 157/4885SMN1; SMN2 3139/4885
US-20180066007-A1 Macrocyclic Compounds And Methods Of Making And Using The Same CCNO, PTGDR, CCNE1 CA2 2606/4885PTGS2 51/4885SMN1; SMN2 2993/4885
US-20170334823-A1 METHODS FOR PRODUCING FUELS, GASOLINE ADDITIVES, AND LUBRICANTS USING AMINE CATALYSTS GK, ADH1A, ADH5 CA2 1675/4885PTGS2 1710/4885SMN1; SMN2 3110/4885
US-20080027060-A1 DIPEPTIDE NITRILES CTSL, CTSS, CTSB CA2 411/4885PTGS2 2257/4885SMN1; SMN2 4307/4885
US-20170327448-A1 METHODS FOR PRODUCING FUELS, GASOLINE ADDITIVES, AND LUBRICANTS USING AMINE CATALYSTS GK, MSMO1, DGKG CA2 2626/4885PTGS2 800/4885SMN1; SMN2 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.